Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins.</li><li>C1 has been commercialized in industrial applications and is in development for production of pharmaceutical grade proteins.</li><li>C1 exhibits potential to economically produce recombinant proteins, biologic vaccines, virus-like particles, antibodies, Fc-fusion, enzymes, AAVs and other biopharmaceuticals.</li></ul>

Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins.C1 has been commercialized in industrial applications and is in development for production of pharmaceutical grade proteins.C1 exhibits potential to economically produce recombinant proteins, biologic vaccines, virus-like particles, antibodies, Fc-fusion, enzymes, AAVs and other biopharmaceuticals.

DYAI: Layers of Commercialization Agreements

Dyadic International

DYAI: Layers of Commercialization Agreements